Lamivudine Main Page

Medical Advocates
Lamivudine (Epivir)

Main Page

New and Noteworthy
Lamivudine PI
Drug Alerts
Guidelines
Database of ARV Drug Interactions
Journal Data
Conference Data
Perinatal Data
Pediatric Data

ARV Drugs Main Page Main New/Newsworthy Home Page

This web page is best viewed by using INTERNET EXPLORER
Last Update: June 29, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

June 2008

Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy.
Nelson M, Azwa A, Sokwala A, et alAIDS. 2008 Jul 11;22(11):1374-6.

Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis.
Loomba R, Rowley AK, Wesley R, et al Clin Gastroenterol Hepatol. 2008 Jun;6(6):696-700.

May 2008

Failure of lamivudine to reverse hepatitis B virus-associated changes in ERK, Akt and cell cycle regulatory proteins.
Chin R, Earnest-Silveira L, Koeberlein B, et al; Antivir Ther. 2008;13(2):221-30.

Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.
Kennedy PT, Phillips N, et al Liver Int. 2008 May;28(5):699-704.

FULL TEXT ARTICLE
Determination of lamivudine-resistant variants of hepatitis B virus by denaturing gradient gel electrophoresis:
A novel approach to monitoring drug resistance.
Bielawski KP, Al-Soud WA, Stalke P,et al Med Sci Monit. 2008 May;14(5):CR281-285

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive
cancer patients undergoing cytotoxic chemotherapy.
Cil T, Altintas A, Pasa S, Bayan K, et al Leuk Lymphoma. 2008 May;49(5):939-47.

Drug Alerts

Lamivudine/Abacavir/Tenofovir

Early Virologic Non-Response in Patients with HIV Infection Treated With Lamivudine,
Abacavir and Tenofovir
GSK
July 2003

ARV Drugs Main Page Main New/Newsworthy Home Page

Lamivudine Main Page